MAIA Biotechnology raises $1.3 million through private placement Dec 17, 2025 06:09AM
MAIA Biotechnology receives FDA fast track designation for lung cancer drug Jul 28, 2025 08:01AM
MAIA Biotechnology publishes data on second-generation cancer prodrugs Jul 17, 2025 09:17AM
MAIA Biotechnology doses first patient in Taiwan lung cancer trial expansion Jul 9, 2025 09:16AM
MAIA Biotechnology (MAIA) adds two oncologists to its SAB Jun 24, 2025 08:18AM


Jun 18, 2025 09:15AM MAIA Biotechnology (MAIA) Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
Jun 5, 2025 11:10AM MAIA Biotechnology (MAIA) Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial
Jun 5, 2025 09:03AM Maia Biotechnology (MAIA) stock rises following positive trial results
Jun 5, 2025 08:04AM MAIA Biotechnology (MAIA) Announces Positive Efficacy Update for Phase 2 THIO-101 Trial
May 27, 2025 04:31PM MAIA Biotechnology (MAIA) Announces 446K Share Private Placement at $1.50/sh
May 5, 2025 04:07PM MAIA Biotechnology (MAIA) Announces 720K Share Placement at $1.50/sh
Apr 1, 2025 08:32AM MAIA Biotechnology (MAIA) CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders
Mar 20, 2025 09:21AM MAIA Biotechnology (MAIA) Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug
Mar 19, 2025 11:01AM MAIA Biotechnology (MAIA) Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO
Feb 26, 2025 08:48AM MAIA Biotechnology (MAIA) Announces Design for Expansion of THIO-101 Phase 2 Trial
Feb 24, 2025 04:31PM MAIA Biotechnology (MAIA) Announces Non-Brokered Private Placement of Approximately $1.43 Million
Feb 18, 2025 03:44PM MAIA Biotechnology (MAIA) Announces Private Placement of $2,715,000
Feb 18, 2025 03:08PM MAIA Biotechnology (MAIA) Halted, News Pending
Feb 4, 2025 08:51AM MAIA Biotechnology (MAIA) Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
Jan 7, 2025 09:12AM MAIA Biotechnology (MAIA) Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications
Dec 16, 2024 08:39AM MAIA Biotechnology (MAIA) Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas
Dec 3, 2024 08:17AM MAIA Biotechnology (MAIA) Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
Oct 29, 2024 05:59AM MAIA Biotechnology (MAIA) Prices 1.08M Share Offering at $2.259/sh
Sep 10, 2024 06:16AM MAIA Biotechnology (MAIA) Reports Positive Survival Updates in Phase 2 Study of THIO